Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HKT288 in Advanced Solid Tumors
NCT02947152Phase 1Terminated
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 1, open-label trial of HKT288 in epithelial ovarian cancer (EOC) and renal cell carcinoma (RCC) (3 arms), sponsored by Novartis. Primary endpoints: Incidence of dose limiting toxicities at 21 days, Incidence of Adverse Events and Serious Adverse Events up to 6 months and 1 more. Started Dec 2016; status: terminated.
02
Drugs
HKT288
03
Conditions
epithelial ovarian cancer (EOC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02947152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947152.